Harlan F. Weisman - 03 Dec 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc.

Role
President and CEO, Director
Signature
/s/ Harlan F. Weisman, by Kirk Allen Coleman, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Dec 2022
Net transactions value
$0
Form type
4
Filing time
06 Dec 2022, 20:39:00 UTC
Previous filing
20 May 2022
Next filing
19 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TFFP Stock Options (Right to Buy) Award $0 +1,792,450 $0.000000 1,792,450 03 Dec 2022 Common Stock 1,792,450 $1.19 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Options shall vest during the period of Dr. Weisman's service as CEO of the Company as follows: Options to purchase 298,750 shares of Common Stock ("Six Month Options") shall vest upon the six-month anniversary of the date of grant and Options to purchase 49,790 shares of Common Stock shall vest in 30 monthly installments commencing on the seven-month anniversary of the date of grant. In the event of the Company's termination of Dr. Weisman's service as CEO ("Termination of Service") as a result of hiring a permanent CEO all unvested Options shall immediately expire.